Screener
Crinetics Pharmaceuticals CRNX Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Net loss | (127,845) | (96,774) |
| Net loss per share: | ||
| Net loss per share — basic and diluted | $(1.23) | $(1.04) |
| Weighted average shares — basic and diluted | 104,099 | 93,102 |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on investment securities | $(3,147) | $1,033 |
| Unrealized gain on foreign currency | 28 | 6 |
| Total other comprehensive income (loss) | (3,119) | 1,039 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's shares (diluted)?
- Crinetics Pharmaceuticals (CRNX) reported shares (diluted) of 104.1M in Q1 2026.
- How has Crinetics Pharmaceuticals's shares (diluted) changed year-over-year?
- Crinetics Pharmaceuticals's shares (diluted) increased by 11.8% year-over-year, from 93.1M to 104.1M.
- What is the long-term trend for Crinetics Pharmaceuticals's shares (diluted)?
- Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's shares (diluted) has grown at a 26.4% compound annual growth rate (CAGR), from 146.8M to 375.2M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Crinetics Pharmaceuticals's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude